Stock Ratings / Health Care / GALT / financials

CYPH (40) CTNM (40) SPRY (27) AVIR (40) ⌘ Pro Terminal →

Galectin Therapeutics Inc. (GALT) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$3.52 -0.56% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.51

Galectin Therapeutics Inc. (GALT) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $355.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.51 (-0.29%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-7.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GALT)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (42/100 Composite)

🔍 WHY GALT SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+12/20 pts (29% of score)

FRED Regime × Technicals: 29% of 52W Range • RSI-14 at 40.7 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$3.94-8.1% Next Q

Q2 (-2Q)

Grade D$3.62-11.9% Next Q

Q3 (-1Q)

Grade D$3.19+10.3% Next Q

Current

Grade D-$3.52-7% Hist 90D α

Trajectory: C- (50) → D- (42)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a GALT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While GALT currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.81) and Max Pain ($3.70) forces dealer call-delta covering toward $7.49.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GALT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “GALT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 42%NO 58%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How GALT Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $4.00B

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-0.5%	-$30.8M	-$23.9M	-45%
FY 2024	$4.00B	52%	-1.1%	-$47.0M	-$41.8M	-45%
FY 2023	$4.00B	52%	-1%	-$41.1M	-$33.0M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GALT)

✓Walkthrough of GALT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

GALT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +55.07%📐 WEDGE COMPRESSION COIL

2026-10-30O $3.52H $3.54L $3.27C $3.52VOL 174.7K

RES: $3.87SUP: $3.14SMA50: $3.81SMA200: $3.21

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GALT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GALT Butterfly Map → + Track GALT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on GALT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GALT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for GALT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GALT)

Health Care Rank #574 of 1016 ⚔️ CYPH vs GALT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GALT vs. CYPH, CTNM, SPRY, AVIR)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Galectin Therapeutics Inc. (GALT) ranks #574 by composite RQD confidence (42/100, grade D-) and #499 by equity capitalization ($355.8M). Within this direct 5-issuer industry benchmark cohort, CYPH leads on earnings valuation at 71.3x trailing P/E, while CYPH leads on capital efficiency and profitability with -23.3% ROIC and — gross margin. GALT currently leads its immediate peer cohort in composite quantitative strength at 42/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
GALT ACTIVE Galectin Therapeutics Inc.	D-	42/100	—	—	-35.0%	-0.56%	$355.8M	Benchmark Subject
CYPH Cypherpunk Technologies Inc.	D-	40/100	71.3x	—	-23.3%	+2.16%	$356.7M	/cyph-vs-galt →
CTNM Contineum Therapeutics Inc. (Class A)	D-	40/100	—	—	-29.0%	+1.97%	$351.0M	/ctnm-vs-galt →
SPRY ARS Pharmaceuticals Inc.	E	27/100	—	—	-35.0%	+0.27%	$364.0M	/spry-vs-galt →
AVIR Atea Pharmaceuticals Inc.	D-	40/100	—	—	-35.0%	+0.94%	$345.7M	/avir-vs-galt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001133416

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Galectin Therapeutics Inc. (GALT) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$30.8M, operating cash flow of -$23.9M, and free cash flow of -$23.9M (+42.8% YoY). On the balance sheet, GALT closed FY2025 with $19.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$30.8M	-$23.9M	-$23.9M	$19.5M	—
FY2024 (FY)	2024-12-31	$0	-$47.0M	-$41.8M	-$41.8M	$17.5M	—
FY2023 (FY)	2023-12-31	$0	-$41.1M	-$33.0M	-$33.0M	—	—

3. GALT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GALT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Galectin Therapeutics Inc. (NASDAQ: GALT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $3.52 (-0.56% 1D, market cap $355.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, GALT ranks #574 in composite RQD confidence.

How does GALT compare to CYPH and CTNM in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GALT carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CYPH (Cypherpunk Technologies Inc.) holds a D- grade (40/100 RQD, P/E 71.3x, ROIC -23.3%, cap $356.7M) and CTNM (Contineum Therapeutics Inc. (Class A)) posts a D- grade (40/100 RQD, P/E N/A, ROIC -29.0%, cap $351.0M). Among the 5-stock peer group, CYPH leads on earnings multiple (71.3x) while CYPH leads on capital efficiency (-23.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GALT?

Per GALT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001133416), Galectin Therapeutics Inc. generated $0 in revenue, -$30.8M in net income, and -$23.9M in free cash flow against $19.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GALT trading relative to its 50-day, 200-day, and 52-week technical levels?

GALT last traded at $3.52 (-0.56% on volume of 263,875 shares), positioning the stock -7.61% below its 50-day simple moving average ($3.81) and +9.66% above its 200-day simple moving average ($3.21). Across its 52-week range of $2.03 to $7.13, GALT sits at the 29.2% percentile with a 14-day RSI of 40.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.08 to $3.96).

GALT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Galectin Therapeutics Inc. (GALT)?

In FY 2025 (10-K), GALT converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: GALT RQD Cockpit GALT 12M Forecast GALT Earnings & Move GALT Dividends & DRIP GALT Insiders & 13F GALT Whale Options GALT Profit Sankey GALT News & Why